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ABSTRACT
Circulating tumor cells (CTCs) are frequently associated with epithelial-
mesenchymal transition (EMT).The objective of this study was to detect EMT 
phenotype through Vimentin (VIM) and Slug expression in cytokeratin (CK)-negative 
CTCs in non-metastatic breast cancer patients and to determine the importance of 
EGFR in the EMT phenomenon. In CK-negative CTCs samples, both VIM and Slug 
markers were co-expressed in the most of patients. Among patients EGFR+, half of 
them were positive for these EMT markers. Furthermore, after a systemic treatment 
68% of patients switched from CK- to CK+ CTCs. In our experimental model we found 
that activation of EGFR signaling by its ligand on MCF-7 cells is sufficient to increase 
EMT phenotypes, to inhibit apoptotic events and to induce the loss of CK expression. 
The simultaneous detection of both EGFR and EMT markers in CTCs may improve 
prognostic or predictive information in patients with operable breast cancer.
INTRODUCTION
Early detection and characterization of circulating 
tumor cells (CTCs) have a prominent role as a prognostic 
and predictive factor in several types of solid tumors 
[1] and, especially in breast cancer (BC) evolution. 
Nevertheless, our knowledge of the biological properties of 
CTCs is still limited, and it is broadly accepted that during 
tumorigenesis CTCs acquire features of invasiveness 
and motility, surviving in hostile environments, such as 
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the bloodstream [2,3]. These phenotypic changes are 
associated with or are at least partially a consequence of 
the epithelial-mesenchymal transition (EMT) phenomenon 
[4]. The implication of EMT in BC has been established. 
In fact, CTCs of primary tumors express EMT markers 
and the presence of mesenchymal markers is higher in 
metastatic BC patients than in early stage BC patients, 
suggesting that EMT phenotype is directly related to the 
metastatic potential of CTCs. 
The process of EMT involves the formation 
of metastatic cancer cells that gain the expression of 
mesenchymal markers such as vimentin (VIM) or 
Slug and the loss of epithelial markers including the 
epithelial cell adhesion molecule (EpCAM) or cytokeratin 
(CK), acquiring a mesenchymal or semi-mesenchymal 
phenotype [5,6]. Furthermore, the presence of this EMT 
phenotype has been associated not only with the metastatic 
potential of CTCs but also with the capacity of these 
CTCs to present drug resistance [7]. In fact, high levels 
of VIM expression in cancer patients are correlated with 
a poor prognosis [8] and, the simultaneous expression 
of VIM and CK in BC cells seems to be associated with 
lower survival rates in BC patients. Also, Slug has been 
associated with low life expectancy in a variety of human 
cancers [9]. 
Moreover, EGFR signaling is important in normal 
epithelial development and in tumor cell proliferation, 
motility, survival and metastasis and it is known to 
be overexpressed in BCs, especially in triple negative 
BC cases [10]. Interestingly, it has been demonstrated 
that EGFR inhibition suppress EMT and consequently 
decreases cell migration and invasion ability [11].
To the best of our knowledge there are no studies 
that explore the relationship between EGFR expression 
Table 1: Clinical-pathological characteristics according to the baseline status
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and EMT markers (VIM and Slug) in CTCs isolated from 
BC patients. Since EGFR may promote proliferation 
and progression in BC and VIM and Slug are potential 
regulators of cell adhesion and migration, our study aimed 
to determine the correlation between the expression of 
these EMT markers and the up-regulation of EGFR 
expression in CTCs negatives for CK. Finally, we studied 
if CK-CTCs with EMT features could be used as indicators 
to evaluate the prognosis of operable BC patients.
RESULTS 
Correlation of VIM and Slug expression in CTCs 
with clinical and pathological characteristics
Patients included in this study were consistent with 
an unselected early and locally advanced BC population. 
Clinical-pathological characteristics were stratified 
according to the baseline VIM and Slug expression in CK-
negative CTCs status (Table 1). Clinical tumor size was 
the only primary tumor features that correlated with VIM+ 
and Slug+ CTCs (p= 0.048 and p= 0.047, respectively). No 
significant correlation was found between VIM+/Slug+ 
expression in CTCs and the clinical characteristics of 
patients, including age (<50 vs ≥50 years old), histology, 
nodal status (N0 vs N1-2), grade (gI vs gII vs gIII), 
hormonal status (RH+ vs RH-), p53 status (positive vs 
negative) or KI67 (<14 vs≥14). There was no correlation 
between VIM or Slug/CK-negative CTC status and BC 
subtypes (luminal vs triple negative/HER2 amplified) 
(data not shown).
Correlation of VIM and Slug expression in CK-
negative CTCs with EGFR, CD133, TOPO2/
HER2 biomarkers
To identify EMT-like CTCs, 78 blood samples 
multi-CK-negative were stained with antibodies specific 
to CD45 (a leukocyte marker), VIM and Slug as described 
in material and method (Supplementary Fig. 1S). Samples 
with high background staining were discarded. 67 samples 
were considered for VIM analysis. From these samples, 
18 (26.9%) showed VIM expression and 49 (73.1%) were 
negative. 71 samples were analyzed for Slug expression. 
17 (23.9%) of these patients were positive for Slug 
expression and 54 (76.1%) were negative. Interestingly, 
when Slug was positive in CK-negative CTCs, the VIM 
Figure 1: Epifluorescence microscopy images of CTCs stained for VIM and Slug expression. (A-F) CTCs CK-negative/
VIM+/Slug+ from BC patients stained in green for vimentin and red for Slug. Nuclei were stained in blue (DAPI). Representative images 
showing of a different cellular distribution of Slug, (B) cytoplasmic or (E) nuclear. (G-I) VIM and Slug expression in EGFR positive cells. 
(G) SKBR cells used as positive control for EGFR (blue) and negative for VIM (green) and Slug (red). (H-I) Representative images of the 
different phenotypes found in CK-negative/EGFR+CTCs from BC patients. (H) CTC CK-negative/EGFR+/VIM+/Slug- sample. (I) CTC 
CK-negative/EGFR+/VIM+/Slug+ sample. Note: nuclei of the cells were stained with DAPI after the visualization of VIM, EGFR and Slug 
expression. Original magnification 40x (A-C, G); 63 x (D-F); and 100x (H and I).
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marker was co-expressed in 94.4% (17/18) of the cells. 
However, VIM expression was not always co-expressed 
with Slug (1/18; 5.56%). Thus, VIM negative CTCs were 
also negative for Slug (49; 100%). In addition, we found 
that Slug was mainly detected in the cytoplasm (Fig. 1B); 
although some samples showed a nuclear staining pattern 
as well (Fig. 1E).
Additionally, in order to examine the correlation 
of EFGR, TOPO2/HER2 and CD133 with VIM and Slug 
expression, we studied the presence of these biomarkers 
in patients with CK-negative CTCs before any treatment 
(Table 2). 67 patients were analyzed for VIM and EGFR 
expression. In samples EGFR negative we found that 9 
(18.4%) were VIM+ and 40 (81.6%) were VIM-. In EGFR 
positive samples, 10 (55.5%) were VIM- and 8 (44.5%) 
were VIM+ (p= 0.044). In addition, EGFR expression was 
analyzed in 71 patients positive for Slug marker. 9 (17.3%) 
samples were EGFR-/Slug+, 43 (82.7%) were EGFR-/Slug-, 
11 (57.9%) were EGFR+/Slug- and 8 (42.1%) were EGFR+/
Slug+ (p= 0.030). A representative picture of VIM and 
Figure 2: Effects of TGFβ1 and EGF on EMT, apoptosis and CK expression in MCF-7 cells. MCF-7 cells were treated 
with TGFβ1 (0.5 and 10 ng/ml), EGF (20 ng/ml), or a combination of TGFβ1 and EGF (5 or 10ng/ml and 20ng/ml, respectively) for 72 
hours. (A) Western blots analysis using anti-EGFR, anti-phospho EGFR, anti-Slug, anti-VIM, anti-Bcl-2, anti-caspase 9, anti-multi-CK, 
anti-TGFβ R2 anti-β-actin antibodies. β-actin was used as loading control. (B) Densitometric analysis related to control. (C) Luminescence 
detection of Caspase-3, -7 and -8 activities. Enzymatic activity was expressed in relative light units (RLU). Data represent the mean ± SD 
from three independent experiments (*p<0.05, ***p<0.01 vs. control).
Table 3: Relationship between EGFR expression and recurrence in BC patients negative 
for CK expression after systemic treatment








Slug expression in EGFR positive cells is shown in Fig. 
1D and E. We did not find any correlation between CD133 
expression and EMT markers in CK-negative CTCs. 
Moreover, TOPO2/HER2 amplification was detected in 
only 8 of the 67 patients and only 3 samples were VIM+ 
(37.5%; p= 0.366). Slug expression was detected in 3 of 
the 12 (25%) TOPO2/HER2+ patients (p= 0.592) (Table 3).
Modifications in CK, EGFR and apoptotic 
markers after induction of EMT phenomenon in 
MCF-7 cells
To further explain the relationship between EGFR 
expression in CK-negative CTCs and EMT process we 
developed an experimental model using MCF-7 tumor 
cells. MCF-7 cells were stimulated with TGFβ1 and/or EGF 
at several concentrations for 72 h. Firstly, we analyzed by 
western blotting the switch in the pattern of expression 
of VIM, Slug, Pan-CK and EGFR status and changes in 
the apoptosis mediators Bcl-2 and pro-caspase 9 (Fig. 
2). Our results showed that the induction with TGFβ1/
EGF combination maintained EGFR activation, which 
was accompanied by a significant enhanced expression 
of both VIM and Slug markers and the complete 
inhibition in Pan-CK expression. Moreover, TGFβ1/EGF 
combined treatment involved a significant induction in 
Bcl-2 expression and no modifications in pro-caspase-9. 
Furthermore, caspase-3, -7 and -8 activities increased after 
induction with 10 nM TGFβ1 and significantly decreased 
when EGF was added (Fig. 2C). The significant Bcl-
2 and VIM and Slug induction together the caspase 3/7 
and 8 decreasing demonstrate the inhibition of extrinsic 
apoptotic pathway after acquisition of EMT phenotype in 
EGFR+/CK-negative cells.
Finally, immunofluorescence analysis confirmed 
data obtained by western blot. The morphologic changes 
of MCF-7 cells after transformation with TGFβ1 and 
EGF included loss of cell adhesion, reduced cell-cell 
contact, and increased pseudopodia. Moreover, confocal 
microscopy studies showed an increased and robust 
expression of VIM and Slug, which was located in both 
nucleus and cytoplasm and the total disappearance of 
CK staining after TGFβ1/EGF combined treatment (Fig.3 
A-C). This increase was also detected by RT-qPCR 
technique, where the relative mRNA levels ofVIM and 
Slug significantly enhanced whereas CK8 expression 
practically disappeared after combined treatment. 
EGFR expression decreased only after TGFβ1/EGF 
combined treatment suggesting that changes observed 
in the expression of protein level should be due to post-
transcriptional modifications (Fig. 3D). These results 
confirm the loss of epithelial phenotype and the acquisition 
of mesenchymal markers in CK negative/EGFR+ MCF7 
cells (Fig. 3).
Figure 3: Expression of EGFR, VIM, Slug and CK 
in MCF-7 cells after TGFβ1 and/or EGF induction. 
Confocal microscopy and RT-qPCR examination of MCF-7 
cells treated with TGFβ1 (0 and 10 ng/ml), EGF (20 ng/ml), 
or a combination of TGFβ1 and EGF (10 ng/ml and 20 ng/ml, 
respectively) for 72 h. Representative immunofluorescence 
and light microscopic images of EGFR, VIM, Slug and CK 
staining. Microscope fields shown are representative of at 
least three different assessments. (A) Non-treated control cells 
showed marked staining for CK and a low EGFR expression. 
(B) TGFβ1-treated cells displayed the expression of VIM and 
Slug and a decrease in CK staining. (C) TGFβ1/EGF combined 
treatment induced a high expression of EGFR, VIM and Slug 
and the total disappearance of CK. Nuclei are stained with 
DAPI (blue). Original magnification 20x. (D) RT-qPCR analysis 
of mRNA EGFR, CK8, Slug and VIM expression levels. Data 
represent the mean ± SD from three independent experiments 
(*p<0.05, ***p<0.01 vs. control non-treated cells).
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Treatment with TGFβ1 or TGFβ1/EGF promotes 
cell motility 
Since EMT is generally associated with a migratory 
phenotype that is indispensable for cancer metastasis, 
we performed wound-healing assays in MCF-7 cells 
treated with TGFβ1 or TGFβ1/EGF. Our purpose was to 
demonstrate that continued activation of EGFR and the 
corresponding CK inhibition is associated with a higher 
migratory potential. Our results showed that TGFβ1 or 
TGFβ1/EGF exposition significantly increased the motility 
in MCF7 cells in a time-dependant manner with respect 
to control non-induced cells (Fig. 4A). This enhanced 
migration was more evident in the combined treatment in 
comparison with the TGFβ1 induction alone (Fig. 4B). 
EGFR and BC recurrence after systemic 
treatment
78 patients classified as CK negative received 
systemic treatment. At the end of treatment it was notable 
that only 25 patients have CK-negative CTCs and, thus, 
53 switched from CK negative to CK positive CTCs. 22 
cases of the 25 CK negative CTCs were EGFR negative 
and only one (4.5%) patient showed cancer recurrence. 
Interestingly, two patients (66.66%) EGFR+ CK negative 
presented relapse of the disease (p=0.032) (Table 3).
DISCUSSION 
The systemic nature of BC is defined by the 
dissemination of early tumor cells, even with relatively 
small tumors. In this scenario, the metastatic process 
involves the dissemination of CTCs by the blood and 
the lymphatic system prior to the colonization of distant 
organs. Several studies have observed the presence of 
CTCs in peripheral blood as the precursor of clinically 
manifest distant metastases [12].
The metastatic process is comprised of phenotypic 
alterations that are mediated by genetic changes. Among 
these phenotypic variations the EMT process modulates 
cell survival, migration and resistance to anoikis and 
apoptosis [13]. Epithelial cells undergoing EMT lose their 
characteristics and acquire a mesenchymal phenotype, 
which include loss of epithelial markers (E-cadherin and 
CK) and gain of mesenchymal markers (N-cadherin and 
VIM) [14].
Currently, the majority of techniques used to 
isolate and detect CTCs are based on the expression of 
epithelial markers. Consequently, if the EMT process 
is essential to the migration and survival of tumor cells 
before the colonization of target organs, then, an important 
aggressive subpopulation of tumor cells may not be 
detected. Recently, it has been shown that patients with 
poor prognosis factors had CTCs undetectable by routinely 
used techniques.
In this study, we evaluated the expression of EMT 
markers in a group of primary BC patients, who were 
negative for CK in the basal analysis. Moreover, we 
further explored if EGFR expression in these patients was 
correlated with the acquisition of the EMT phenotype. To 
test our hypothesis that an important cell tumor fraction is 
not detected and, therefore, we can obtain false-negative 
samples, we analyzed VIM and Slug in CK-negative CTCs 
in BC patients. Approximately, 27 percent of samples 
negative for CK expression were positive for VIM and 24 
percent for Slug, respectively. Similar percentages have 
Figure 4: Wound healing assays in MCF-7 cells after 
induction with TGFβ1 and/or EGF. (A) Migration of 
the cells to the wound was visualized at 0, 24 and 48 h with an 
inverted phase-contrast microscope. Original magnification 10x. 
(B) Quantification of cell migration was done by counting the 
free pixels inside and outside of the detection zone (Data were 
analyzed as percentages of the control cells in three independent 
experiments. *p < 0.05 and **p < 0.01 were considered 
significant).
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been obtained by Raimondi’s group, which showed that 
34% of CK negative patients were VIM and fibronectin 
positive [15]. In addition, our results showed that in 
most of the CK-negative CTCs, Slug and VIM were co-
expressed. An “in vivo” model with transplantable human 
breast tumor cells uniquely capable of spontaneous EMT 
events was used to demonstrate that in primary xenograft 
tissues Slug was overexpressed in VIM+ areas [16]. These 
results indicate the need to optimize CTCs isolation and 
detection methods including the surface EMT markers. 
New methods based in isolating by size may be a powerful 
tool to detect different CTC subpopulations [17].
Interestingly, we found a direct relationship between 
tumor size and VIM and Slug expression in CK-negative 
CTCs. In fact, it has been demonstrated that EMT 
progression is responsible for increased tumor growth 
and metastasis in prostate and BC xenograft experiments 
[18]. Moreover, in prostate carcinoma the increase of the 
E-cadherin epithelial marker was inversely correlated with 
size of the metastasis and this expression was increased 
compared to the primary lesion [19]. Our results suggest 
the important role of VIM/Slug EMT markers in tumor 
growth of primary BC.
Our data show that Slug was mainly distributed 
in the cytoplasm of the cells, although nuclear staining 
was also detected. A recent study demonstrated that 
cytoplasmic Slug induces invasive finger-like protrusions 
termed invadopodia in pancreatic tumors cells by 
intracellular F-actin polymerization. This process of 
modulation of the cytoskeletal structure is directly related 
to a higher invasive and metastatic capacity [20]. 
Several authors have correlated EGFR expression 
with a poor prognosis in BC patients. It has also been 
demonstrated that the EGFR pathway controls several 
important biological processes, including cellular 
proliferation, angiogenesis and inhibition of apoptosis 
[21]. The EMT program is associated with cellular 
pathways that confer new characteristics to the cells, such 
as apoptosis resistance, migration capacity and chemo and 
radioresistance [22]. We found a statistically significant 
correlation between EGFR+ CTCs and CK-/VIM+/Slug+ 
CTCs in approximately 40% of patients. In the same 
context, a recent study showed that HER2 overexpression 
in BC cells is accompanied by partial EMT-like transition 
through the activation of Wnt/β-catenin signaling pathway 
leading to transactivation of EGFR and promoting EMT-
like transition [23]. Also, Lo et al. examined the role of the 
EGFR pathway in tumor cell lines and histological types 
of primary BC patients. In this study, they reported that 
high EGFR expression induced EMT, with subsequent 
Twist, Snail and Slug induction [24]. However, no clinical 
studies have been done to study the relationship between 
EGFR status, EMT phenotype and CTCs in non-metastatic 
BC, due to the extremely difficult to characterize CTCs 
during the EMT process. Our results suggest that CK-
negative CTCs with high EGFR expression induced EMT, 
and this phenotypic transition could involve the EGFR-
mediated activation of VIM and the subsequent VIM-
activated Slug gene expression.
To strengthen our hypothesis, we determined the 
role of EGFR in mediating EMT and CK expression 
on the MCF7 tumor cell line that possesses epithelial 
characteristics. MCF7 was stimulated with TGFβ1, a 
potent initiator of mesenchymal transformation [4], or 
TGFβ1/EGF to induce EMT phenotype. We found that 
the activation of EGFR up-regulated VIM and Slug 
mesenchymal markers and down-regulated pan-CK 
epithelial markers. Our results suggest that the activation 
of EGFR signaling by its ligand and the presence of 
TGFβ1 induces EMT and subsequently inhibits CK 
expression (Supplementary Fig. 2S). Recently, it has been 
demonstrated that CTCs from patients with metastatic 
BC had predominantly mesenchymal phenotypes [25] 
and that EGF can induce EMT-like effects including the 
up-regulation of Twist through the EGFR pathway [24], 
which agree with our experimental data. Interestingly, we 
also detected that cells treated with TGFβ1 alone showed a 
dose-dependent increment in caspase 3/7 and 8 activity on 
the contrary, TGFβ1/EGF combination overexpressed Bcl-
2 and significantly decreased caspases activity in MCF-
7/EMT +/CK-negative cells. TGFβ1–induced apoptosis 
has been considered to be largely dependent on caspase 
activation [26]. In epithelial cells, TGFβ1 is able to induce 
both cell apoptosis and EMT in the same cell type, in a 
cell cycle-related manner, in which apoptosis took place at 
G2/M phase and EMT in G1/S phase. Moreover, the EGFR 
activation in TGFβ1 treated cells was sufficient to increase 
EMT phenotypes, to inhibit apoptotic events and to induce 
loss of CK expression. Down-regulation of epithelial cell 
marker expression occurs concomitantly with, and as a 
driver of, a wound-healing response and due to loss of 
cell to cell contact between cell-basement membranes 
and their structural/functional polarity [27]. Signaling 
through the EGF receptor is known to influence the 
apoptotic resistance and the invasive potential of certain 
cancers, and this may be associated with the adoption 
of a transdifferentiated phenotype. In human renal cells, 
it has been demonstrated that EGF promotes EMT by 
offsetting the pro-apoptotic effects of TGFβ1 without 
preventing its EMT-inducing effect, thereby facilitating 
the improved survival of cells undergoing EMT [27], in 
concordance with our results of EGFR activated human 
BC cells. Moreover, in squamous carcinoma both the over 
expression of Bcl-2 or EGFR activation induced EMT, 
promoting cell migration and invasion via the ERK1/2 and 
PI3K-regulated MMP-9/E-cadherin signaling pathways 
[28]. These experimental data could explain the recurrence 
related to CK negative/EGFR+CTCs of non-metastatic BC 
patients. However, further studies with a higher number of 
patients are needed to confirm this hypothesis.
On the other hand, in a recent study, Chang et al. 
[29] found a correlation between the development of 
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resistance to gefitinib and Slug expression in non-small 
cell lung cancer patients with EGFR mutation. Our 
preliminary results showed that patients with CK-negative 
CTCs that expressed EGFR showed poor progression 
free survival (PFS) after receiving systemic treatment. 
Although we did not correlate VIM and Slug expression 
with PFS these results suggest that EGFR expression in 
CTCs is necessary for the progression of the disease and 
that EMT markers may contribute to the survival of CTCs 
in peripheral blood. Nevertheless, the number of patients 
is too low to really give any clear conclusion and it opens 
a possibility for studies implicating higher number of 
patients.
However, the complexity of the dissemination 
process still needs further clarifications since a 
heterogeneous population of CTCs is believed to spread 
into the circulation. In fact, we found CTCs with three 
different phenotypes: i) CK+/EGFR+/Vim-/Slug-; ii) CK-/
EGFR+/Vim-/Slug-; and iii) CK-/EGFR+/Vim-/Slug +. 
Moreover, we found that patients CK-/EMT+ at baselines 
were CK+ after treatment. Actually, it has been shown 
that after targeted therapy, CTCs from responding BC 
patients were fewer in number and presented more 
characteristic of an epithelial phenotype than CTCs from 
refractory patients, which were more numerous and 
retained or acquired a mesenchymal phenotype [25]. In 
these patients with metastatic BC patients were detected 
a significant number of CTCs exhibiting a partial or 
a full-blown EMT phenotype, supportive of an EMT-
driven mechanism. Interestingly, a large fraction of the 
CTCs were either double epithelial/mesenchymal or 
mesenchymal-positive, particularly among the HER2+ 
and triple negative subtypes [25]. These findings could 
be explained by the transient and reversible nature of 
EMT processes in CTCs since an epithelial phenotype is 
favorable in the latter stages of the metastatic cascade and 
in the metastasis growth. EMT occurs in primary tumors, 
providing the cells with an enhanced ability to intravasate 
and generates CTCs. On the other hand, MET phenomena 
would occur to favor the metastatic growth in secondary 
organs, emphasizing the dynamic plasticity of the process 
[16,19]. It is important to highlight that our study was 
focused in patients that presented a negative expression of 
CK. We show that is necessary to optimize CTC detection 
methods by including EMT markers able to distinguish 
between diverse phenotypes that could be linked to tumor 
aggressiveness.
Detecting changes in cell phenotype could be 
the key for developing new therapeutic targets or more 
effective therapeutic regimens. Furthermore, present 
results may indicate that different signaling pathways 
are activated in CTCs to promote EMT, leading not only 
to the possibility of progression but also survival in a 
hostile microenvironment. Our findings suggest that the 
simultaneous detection of EGFR, EMT antigens (VIM 
and Slug) and CK in CTCs by enrichment methods may 
contribute to the better detection of CTC subpopulations 
and improve prognostic or predictive information during 
systemic therapy in patients with operable BC.
MATERIALS AND METHODS
Patients
78 stage I to IIIC BC patients were enrolled from 
the Breast Cancer Unit of the University Hospital of 
Jaén and Hospital del Mar of Barcelona from March 
2009 to September 2010. The inclusion criteria were 
the histological diagnosis of BC and the availability of 
tissue for biomarker studies. The local ethics committee 
approved this study and eligible patients were acquired. 
Surgical procedures and systemic therapy were given at 
the discretion of the treating physician with or without 
targeted therapy, namely trastuzumab for human epidermal 
growth factor 2 (HER2+) BC patients. The medical charts 
of these patients were reviewed and their clinical details 
were included in a database.
We used a combination of immunohistochemical 
(IHC) markers for the classification of BC patients based 
on the pattern of expression of hormonal receptors (HR) 
and HER2 that identified three major distinct molecular 
BC subtypes: luminal tumors, which are HR positive and 
HER2-, HER2 amplified tumors and those tumors with no 
expression of any of the three receptors [30,31]. Tumor 
specimens from archival tumor biopsies of each patient 
were obtained and analyzed for different markers.
CTC enrichment 
Patients donated peripheral blood at the time of 
initial diagnosis. Control blood samples were drawn 
from 16 healthy volunteers with no history of malignant 
disease. 30 ml of blood was collected from each donor 
in three different Cell Save Preservatives blood collection 
Tubes (Veridex, LLC, Johnson & Johnson Company). 
Blood samples were maintained at room temperature 
and processed according to the protocols we have 
previously established [32]. For CTCs enrichment, we 
used the Carcinoma Cell Enrichment and Detection kit, 
MACS technology (Miltenyi Biotec), using magnetic 
beads labeled with a multi-CK-specific antibody (CK3-
11D5) that recognizes CK 7, 8, 18 and 19. Patients were 
considered CTCs-positive if ≥1 CTC per 10 ml blood 
was detected. Samples negative for CK after selective 
immunomagnetic cell separation were considered CK-
negative patients. 
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Cell cultures and immunocytochemistry assay 
feasibility
BC cell lines were obtained from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK). In 
the recovery experiments, we analyzed control samples 
with low numbers (10, 5, 1 cells) from MCF-7 (ECACC), 
SKBR3 (ECACC) and T47D (ECACC) human BC 
cell lines. Cells were spiked in 10 ml of venous blood 
from healthy volunteers and control experiments were 
performed at least in triplicate. Cytospins were prepared 
afterward by density gradient centrifugation and by 
immunomagnetic selection in the same way that the 
patient samples. Recovery rates of tumor cells spiked into 
normal blood at the low level control numbers were in the 
range of 40-60%. As negative controls, 16 blood samples 
from healthy volunteers without evidence of an epithelial 
malignancy were examined. Peripheral blood was drawn 
from the middle of vein puncture after the first 3 ml of 
blood were discarded. This precaution was undertaken in 
order to avoid contamination of the sample with epithelial 
cells from the skin during sample collection and to 
assure a high specificity of the method. We next tested 
technical feasibility determining protein expression by 
immunofluorescence (IF) and DNA amplification by FISH 
in isolated CTCs. We evaluated the range of expression 
seen in CTCs by presence or absence of staining using an 
anti-CK and EGFR antibody. Moreover, CD133 (AC133, 
Isotype: mouse IgG) (MiltenyiBiotec) expression in CTCs 
was analyzed by IF. TOP2A and HER2 amplification by 
FISH were determined in isolated CTCs. In the same 
way, CTCs negatives to CK expression were evaluated 
to EGFR, TOP2A/HER2 and CD133 expression, the 
methodology employed is shown in supplementary Fig. 
1S.
HUVEC cell line was used as positive control for 
VIM and Slug expression. We evaluated their expression 
by presence or absence of staining using anti-VIM and 
anti-Slug antibodies (Santa Cruz Biotechnology). SKBR3 
tumor cell line was used as negative control for both 
markers. 
CK and EGFR expression in CTCs
EGFR-positive cells were identified by 
immunofluorescence assays. The presence of CK cells 
was revealed by incubation with a freshly prepared Fast 
Red TR/Naphthol AS-MX substrate solution and identified 
under a microscope. EGFR+ cells were revealed by 
incubation with primary monoclonal anti-human EGFR 
(Dako) (dilution 1:25), followed by incubation with Alexa 
Flour 350 (Molecular Probes, Invitrogen). Epithelial 
tumor cells were identified and enumerated based on 
their red staining for CK-positive cells and blue staining 
for EGFR+ cells. The SKBR3 tumor cell line was used 
as positive control for EGFR. Identification and counting 
were done with a computerized fluorescence microscope 
Zeiss AXIO Imager.
Vimentin and Slug expression in CTCs 
The subpopulation of patients with CTCs negative 
for CK expression was selected by the immunomagnetic 
multi-CK enrichment method. The slides, negative for CK 
expression, were then stained with conjugated VIM-FITC 
(mouse monoclonal antibody) and Slug (rabbit polyclonal 
antibody) visualized with anti-rabbit Alexa Fluor 633 
(Molecular Probes). Finally, CD45 (mouse monoclonal 
antibody, Santa Cruz Biotech) expression was revealed 
by incubation with an Alexa 405, to detect hematopoietic 
cells. Cells VIM+ and/or Slug+, CD45-were considered 
EMT-positive CTCs. After the identification of these 
markers, nuclear staining with DAPI was performed. 
Identification and counting were done with a computerized 
fluorescence microscope Zeiss AXIO Imager.
EMT induction by TGFβ1 and/or EGF
2 x 105 MCF-7 cells were seeded a day prior to 
starting the treatment at ~30-40% confluence in 6 well 
plates, then stimulated with recombinant human TGFβ1 
(Santa Cruz Biotechnology) and/or EGF (Abcam, 
Cambridge) in DMEM without FBS medium at 0, 5 and 
10 ng/ml or 0 and 20 ng/ml, respectively.
Western blotting analysis
Protein extraction and Western blot analysis were 
performed in MCF-7 cells induced or non-induced with 
TGFβ1 and EGF. MCF-7 cells (5 x 105) were plated in 
6 wells plate followed by incubation with TGFβ1 and/
or EGF at several concentrations (0, 5 and 10 ng/ml for 
TGFβ1 and 0 or 20ng/ml for EGF). After 72 h of treatment 
cells were lysed in sample buffer (62.76 mMTris– HCl 
pH 6.8, 5% 2-mercaptoethanol, 2% SDS, 10% glycerol, 
0.5%bromophenol blue, and 100 mM dithiothreitol). 
Proteins (30 μg) were separated by SDS-PAGE (10%) 
in a Mini Protean II cell (Bio-Rad, Hercules, CA) and 
were transferred to a nitrocellulose membrane (80 V at 
room temperature for 30 min). Blots were treated with 
blocking solution (PBS TWIN 0.5% non-fat milk) for 
1 h at room temperature and then reacted with primary 
antibody against VIM, Slug, Bcl-2, caspase 9, multi-
CK, TGFβ R2 (Abcam, Cambridge) and EGFR (Santa 
Cruz Biotechnology, CA) at 1:1000 dilution overnight 
at 4ºC. Then, membranes were washed and reincubated 
for 1h with a horseradish peroxidase-conjugated anti-
IgG (Abcam, Cambridge) diluted at 1:1000. Protein–
antibody complexes were visualized by enhanced 
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chemiluminescence (ECL Prime western blotting 
Detection Reagent, GE Healthcare, Buckinghamshire) 
and using a densitrometric analysis system (J1·47t image 
processing system, National Institute of Health, USA).
Caspase-3, -7 and -8 activities
Caspase-3, -7 and -8 activities were measured 
using Caspase-Glo® 3/7 and Caspase-Glo® 8 Assay 
kits (Promega, Madison, WI, USA) according to 
manufacturer’s instructions. Briefly, MCF-7 cells were 
seeded at 5x104 cells/well in 96-well, white-walled plates 
and treated with TGFβ1 and/or EGF, after cells were 
grown to 50% confluence. After incubation for 72 hours 
an equal volume of Caspase-Glo® reagent was added. The 
plates were shaken at 500 rpm for 30 sec, incubated for 1 
h, and the luminescence that is proportional to caspase 3/7 
and 8 activities was determined by luminometer. Data are 
presented as the mean ± SD from three replicates.
Confocal microscopy
Confocal images were obtained using a Zeiss LSM 
710 confocal/multi photon laser scanning microscope 
equipped with Argon/2 laser (458, 477, 488, 514 nm) 
and a Titanium Sapphire laser (750 nm). The cells were 
viewed with several apochromatic objectives and images 
of different fields were taken. The microscope was set 
up to take multichannel images and the excitation and 
emission filter sets configured individually so that there 
is no fluorescence bleed-through between the channels. 
The argon (488 nm) laser with appropriate, emission 
filters was used for the visualization of Alexa Fluor 
488. Alexa Fluor 488 was utilized to visualize EGFR, 
VIM and CK and an Alexa Fluor 633 was used to Slug. 
Adherent monolayer cultures of 1 x 104 MCF7 cells per 
well were grown on glass coverslips for 72 hours with 
TGFβ1 (10 ng/ml) and with TGFβ1/EGF (10 ng/ml and 
20 ng/ml, respectively) combination on culture slide 
(Becton Dickinson). Then, cells were washed and fixed 
with 3·7% formaldehyde in Dulbecco’s PBS followed by 
permeabilization in 0·5% NP40. The cells were washed, 
blocked with 5% BSA in PBS, and incubated with primary 
antibody for overnight at 4ºC and with Alexa Fluor 488 
or Alexa Fluor 633-conjugated secondary antibody for 
one hour. The slides were then washed with PBS for 15 
min air dried, and mounted with Vectashield® mounting 
medium with 4′,6-diamidino-2-phenylindole (DAPI) (Cat# 
H-1200, Vector Laboratories). Images of three randomly-
selected microscope fields of each sample were taken. The 
images were captured using a spinning objective confocal 
microscope at X60 magnification.
RNA isolation and real-time PCR analysis
Real-time PCR was performed to assess the effect 
in the gene expression of TGFβ1 and/or EGF treatment 
on EGFR, CK8, VIM and Slug. MCF-7 cells (5 x 105) 
were plated in 6 wells plate followed by incubation with 
TGFβ1 and/or EGF at several concentrations (0 and 10 
ng/ml for TGFβ1 and 0 or 20ng/ml for EGF) for 72 h. 
Total cellular RNA was isolated using QIAcube equipment 
(QIAGEN) in conjunction with the miRNeasy Mini Kit 
(QIAGEN). The QuantiTect Reverse Transcription Kit 
(QIAGEN) was used for cDNA synthesis. Real-time 
PCR was performed using the KAPA SYBR Fast qPCR 
Kit (KAPABIOSYSTEMS) in conjunction with an Eco 
Illumina System (Illumina). The expression levels were 
normalized to corresponding for GAPDH values and are 
shown as fold change relative to the value of the control 
sample. All the analyses were carried out in triplicate. 
Primer sequences are reported in Table 1S. 
Wound healing assay
Migration of MCF-7 cells treated with TGFβ1and/
or EGF for 72 h was measured using the in vitro wound-
healing assay. Cells were seeded into 6-well plates and 
grown to 80% confluence. Wounds were created by 
scraping monolayer cells with a 200 µl pipette tip and 
non-adherent cells washed off with medium. At 0, 24 and 
48 after the creation of wounds, cells were observed with 
a 10 X objective in an Axiovert 40 CFC Zeiss (Carl Zeiss 
meditec group, Germany) photomicroscope. Images were 
acquired with an AxioCam ICc3 Zeiss (Carl Zeiss meditec 
group, Germany) color digital camera. Wound distances 
were measured at each time point and presented in pixels. 
J·147t Software was used to quantify the wound area. 
All experiments were plated in triplicate wells and were 
carried out at least three times
Statistical analysis
We used χ2 or Student’s t-test to assess the 
correlation between VIM and Slug expression in CTCs 
CK-samples of non-metastatic BC with clinical outcomes 
and EGFR expression. The presence of at least 1 CTC per 
10 ml was considered a positive result, according to the 
reported analytic detection limit of our assay (32). We 
evaluated the range of expression of VIM and Slug seen 
in CK-negative CTCs by presence or absence of staining. 
SPSS 14.0 software was used for statistical analysis. Data 
is presented as means or numbers (%). Two-tailed p<0.05 
values were considered statistically significant. 
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